CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $33.52 million. The enterprise value is $12.65 million.
Important Dates
The last earnings date was Tuesday, March 17, 2026, before market open.
| Earnings Date | Mar 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 9.26 million shares outstanding. The number of shares has increased by 12.00% in one year.
| Current Share Class | 9.26M |
| Shares Outstanding | 9.26M |
| Shares Change (YoY) | +12.00% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 32.04% |
| Owned by Institutions (%) | 15.28% |
| Float | 5.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.37 |
| Forward PS | n/a |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.91
| Current Ratio | 4.91 |
| Quick Ratio | 4.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -93.92% and return on invested capital (ROIC) is -61.59%.
| Return on Equity (ROE) | -93.92% |
| Return on Assets (ROA) | -53.62% |
| Return on Invested Capital (ROIC) | -61.59% |
| Return on Capital Employed (ROCE) | -155.27% |
| Weighted Average Cost of Capital (WACC) | -28.12% |
| Revenue Per Employee | $267,101 |
| Profits Per Employee | -$1.80M |
| Employee Count | 15 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.81% in the last 52 weeks. The beta is -5.88, so CervoMed's price volatility has been lower than the market average.
| Beta (5Y) | -5.88 |
| 52-Week Price Change | -61.81% |
| 50-Day Moving Average | 4.78 |
| 200-Day Moving Average | 7.30 |
| Relative Strength Index (RSI) | 34.04 |
| Average Volume (20 Days) | 85,084 |
Short Selling Information
The latest short interest is 270,631, so 2.92% of the outstanding shares have been sold short.
| Short Interest | 270,631 |
| Short Previous Month | 296,365 |
| Short % of Shares Out | 2.92% |
| Short % of Float | 4.92% |
| Short Ratio (days to cover) | 2.87 |
Income Statement
In the last 12 months, CervoMed had revenue of $4.01 million and -$26.97 million in losses. Loss per share was -$2.98.
| Revenue | 4.01M |
| Gross Profit | -17.81M |
| Operating Income | -28.29M |
| Pretax Income | -26.97M |
| Net Income | -26.97M |
| EBITDA | n/a |
| EBIT | -28.29M |
| Loss Per Share | -$2.98 |
Full Income StatementBalance Sheet
The company has $20.86 million in cash and n/a in debt, with a net cash position of $20.86 million or $2.25 per share.
| Cash & Cash Equivalents | 20.86M |
| Total Debt | n/a |
| Net Cash | 20.86M |
| Net Cash Per Share | $2.25 |
| Equity (Book Value) | 18.22M |
| Book Value Per Share | 1.97 |
| Working Capital | 18.22M |
Full Balance SheetCash Flow
| Operating Cash Flow | -23.45M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -706.22% |
| Pretax Margin | -673.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.00% |
| Shareholder Yield | -12.00% |
| Earnings Yield | -80.46% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CervoMed is $23.00, which is 535.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.00 |
| Price Target Difference | 535.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 101.98% |
| EPS Growth Forecast (5Y) | -16.27% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CervoMed has an Altman Z-Score of -0.55 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.55 |
| Piotroski F-Score | 1 |
